Want to see ATEC full AI Analyst Report?
ATEC Stock Chart & Stats
$11.10
$0.31(3.32%)
At close: 4:00 PM EST
$11.10
$0.31(3.32%)
Day’s Range― - ―
52-Week Range$6.82 - $23.29
Previous CloseN/A
Volume519.80K
Average Volume (3M)2.90M
Market Cap
$1.31B
Enterprise Value$2.16K
Total Cash (Recent Filing)$139.91M
Total Debt (Recent Filing)$603.06M
Price to Earnings (P/E)―
Beta0.67
Next Earnings
Aug 04, 2026EPS Estimate
0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.83
Shares Outstanding153,789,300
10 Day Avg. Volume2,239,441
30 Day Avg. Volume2,904,979
Financial Highlights & Ratios
PEG Ratio1.46
Price to Book (P/B)87.63
Price to Sales (P/S)4.13
P/FCF Ratio1.14K
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$16.50Price Target Upside48.65% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)0.32
Revenue Forecast (FY)$882.40M
Bulls Say, Bears Say
Bulls Say
Sustained Revenue Growth & Surgeon AdoptionConsistent double-digit top-line growth and expanding surgeon adoption indicate durable market penetration for Alphatec's spine platforms. Higher case volumes and new surgeon users drive recurring implant demand and create a widening installed-base moat that supports multi-quarter revenue durability and upsell.
High Gross Margins And Improving Operating LeverageVery strong gross margins provide structural buffer versus cost variability and support scalable profitability as revenue grows. Margin expansion plus controlled opex growth drives meaningful drop-through, enabling sustained adjusted EBITDA improvement and funding for product investment without immediate equity dilution.
Positive Cash Generation And Refinanced Debt StructureOperating cash flow turned positive and free cash flow moved positive TTM, improving self-funding capacity. The new syndicated facility materially extends maturities and lowers interest costs, structurally improving liquidity and reducing refinancing risk, which supports longer-term investment and deleveraging plans.
Bears Say
High Leverage And Very Thin EquityThe capital structure remains highly leveraged with minimal equity cushion, limiting flexibility if growth or margins slow. High absolute debt raises covenant and refinancing risk, constraining strategic optionality and making sustained improvements in cash generation essential to avoid capital strain over multiple quarters.
Ongoing GAAP Losses And Negative Net MarginsDespite margin and EBITDA progress, GAAP losses and negative net margins indicate the business has not yet fully converted scale into sustainable accounting profitability. Continued losses limit retained earnings, hinder equity rebuilding, and increase sensitivity to interest expense and macro shocks over the medium term.
EOS Execution Delays And Working-Capital PressureExecution issues on the EOS platform cause lumpiness in system revenue and slow implant pull-through, undermining a key higher-value growth vector. Simultaneously elevated inventory and instrument investments have used cash, raising working-capital needs that constrain near-term deleveraging unless EOS installations and biologics attachment recover.
Alphatec Holdings News
ATEC FAQ
What was Alphatec’s price range in the past 12 months?
Alphatec lowest stock price was $6.82 and its highest was $23.29 in the past 12 months.
What is Alphatec’s market cap?
Alphatec’s market cap is $1.31B.
When is Alphatec’s upcoming earnings report date?
Alphatec’s upcoming earnings report date is Aug 04, 2026 which is in 13 days.
How were Alphatec’s earnings last quarter?
Alphatec released its earnings results on May 05, 2026. The company reported $0 earnings per share for the quarter, beating the consensus estimate of -$0.022 by $0.022.
Is Alphatec overvalued?
According to Wall Street analysts Alphatec’s price is currently Undervalued.
Does Alphatec pay dividends?
Alphatec does not currently pay dividends.
What is Alphatec’s EPS estimate?
Alphatec’s EPS estimate is 0.07.
How many shares outstanding does Alphatec have?
Alphatec has 153,789,300 shares outstanding.
What happened to Alphatec’s price movement after its last earnings report?
Alphatec reported an EPS of $0 in its last earnings report, beating expectations of -$0.022. Following the earnings report the stock price went down -31.672%.
Which hedge fund is a major shareholder of Alphatec?
Currently, no hedge funds are holding shares in ATEC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alphatec Holdings Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.50 (48.65% Upside)
$16.50 (48.65% Upside)
Blogger Sentiment
Bullish
ATEC Sentiment 100%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 3.8M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $996.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.0%
Last 30 Days ▲ 5.6%
Last 30 Days ▲ 5.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-19.70%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
1.78%
Trailing 12-Months
Company Description
Alphatec
Alphatec Holdings, Inc. is a medical technology firm dedicated to engineering and advancing solutions for the surgical management of spinal conditions. Its product array includes the Alpha InformatiX platform, notably the SafeOp Neural InformatiX System, which is engineered to reduce the likelihood of nerve injury during surgery. For access and positioning, Alphatec offers systems such as the Sigma transforaminal lumbar interbody fusion pedicle-based access system, the Sigma PTP Access and Patient Positioning System, and the Squadron lateral retractor, all designed to optimize surgical outcomes. The company's robust line of spinal fixation devices features the Invictus Spinal Fixation System, capable of addressing various thoracolumbar pathologies, alongside its minimally invasive SingleStep System and adaptable Modular Fixation Systems, which enhance screw modularity. Further fixation options include the OsseoScrew system for spinal column restoration and the comprehensive Arsenal spinal fixation platform, catering to a spectrum of degenerative to deformity procedures. Alphatec also provides anterior lumbar plating solutions like the Aspida Anterior Lumbar Plating System for interbody fusion and the AMP Anti-Migration Plate, in addition to cervical fixation options such as the OCT Spinal Fixation System, the Trestle Luxe Anterior Cervical Plate System, and the Insignia Anterior Cervical Plate System. Its portfolio extends to interbody implants, including IdentiTi Porous Ti, Transcend Lateral, and Battalion Posterior Implants. A comprehensive suite of biologics is also available, featuring Cervical Structural Allograft Spacers, 3D ProFuse Demineralized Bone Scaffold, Neocore Osteoconductive Matrix, Alphagraft Demineralized and Cellular Bone Matrix, and Amnioshield Amniotic Tissue Barrier. The company additionally offers EOS imaging products. Alphatec Holdings markets its diverse product range throughout the United States via a network of independent distributors and its own direct sales force. Established in 1990, the company's headquarters are located in Carlsbad, California.
ATEC Stock 12 Month Forecast
Average Price Target
$16.50
▲(48.65% Upside)
Technical Analysis
Ownership Overview
38.29% Insiders
17.43% Mutual Funds
0.91% Other Institutional Investors
32.86% Public Companies and
Individual Investors